全部分类
  • Asciminib (ABL001)
Asciminib (ABL001)的可视化放大

Asciminib (ABL001)

An allosteric inhibitor of Abl1

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

Asciminib (ABL001)的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 1mg
    ¥425.00
    340.00
    - +
  • 5mg
    ¥937.00
    750.00
    - +
  • 10mg
    ¥1437.00
    1150.00
    - +
  • 25mg
    ¥2962.00
    2370.00
    - +
  • 50mg
    ¥4612.00
    3690.00
    - +
  • 100mg
    ¥7137.00
    5710.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajce49648
  • CAS: 1492952-76-7
  • 别名: ABL001
  • 分子式: C20H18ClF2N5O3
  • 分子量: 449.84
  • 纯度: >98%
  • 溶解度: DMSO : ≥ 100 mg/mL (222.30 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

Asciminib is an allosteric inhibitor of Abl1 (IC50 = 0.45 nM).1 It is selective for Abl1 over a panel of more than 60 additional kinases (IC50s = >10 μM), as well as ion channels, nuclear receptors, G protein-coupled receptors (GPCRs), and transporters. Asciminib inhibits the proliferation of Luc-Ba/F3 cells transformed with wild-type Bcr-Abl1 or the drug-resistant mutant Bcr-Abl1T315I (GI50s = 1 and 25 nM, respectively), as well as other drug-resistant mutants.2 It reduces tumor growth in a KCL-22 chronic myelogenous leukemia (CML) mouse xenograft model when administered at a dose of 3 mg/kg twice per day and induces tumor regression at doses of greater than or equal to 7.5 mg/kg twice per day.


1.Wylie, A.A., Schoepfer, J., Jahnke, W., et al.The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Nature543(7647)733-737(2017) 2.Schoepfer, J., Jahnke, W., Berellini, G., et al.Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1J. Med. Chem.61(18)8120-8135(2018)

Protocol

Cell experiment:

Ba/F3 cells are treated with a range concentration of asciminib (0-10000 nM) for 48 h. Cell proliferation is measured using the Britelite luciferase detection assay[1].

Animal experiment:

Mice: Asciminib efficacy in three patient-derived ALL systemic xenograft models (ALL-7015, AL-7119 and AL-7155) is assessed by FACS monitoring of the percentage of CD45+ cells per live cell in blood samples taken at varying time points after dosing with either 7.5 mg/kg BID (group 2) or 30 mg/kg BID (group 3) asciminib for 3 weeks[1].

参考文献:

[1]. Wylie AA, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017 Mar 30;543(7647):733-737.

没有评价数据

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算